Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Subarachnoid Hemorrhage With Human Albumin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (male or female) were at least 18 but younger than 80 years of age.~* Onset of new neurological signs of subarachnoid hemorrhage within 72 hours at the time of evaluation and initiation of treatment with 25% human albumin.~* Clinical signs consistent with the diagnosis of subarachnoid hemorrhage including severe thunderclap headache, cranial nerve abnormalities, decreased level of consciousness, meningismus and focal neurological deficits.~* Computed tomography demonstrated subarachnoid hemorrhage.~* Cerebral angiography revealed the presence of saccular aneurysm(s) in a location that explains the subarachnoid hemorrhage.~* Treatment of cerebral aneurysm was carried out prior to initiation of HA infusion but within 72 hours of symptom onset. Accepted treatments of aneurysms include surgical clipping or endovascular embolization.~Exclusion Criteria:~* Time of symptom onset could be reliably assessed.~* No demonstrable aneurysm by cerebral angiography.~* Evidence of traumatic, mycotic, or fusiform aneurysm by cerebral angiography.~* World Federation of Neurological Surgeons scale of IV and V~* Computed tomography scale of 0-1~* History within the past 6 months, and/or physical findings on admission of decompensated congestive heart failure (NYHA Class IV or congestive heart failure requiring hospitalization).~* Patient received albumin prior to treatment assignment during the present admission.~* Hospitalization for or diagnosis of acute myocardial infarction within the preceding 3 months.~* Symptoms or electrocardiographic signs indicative of acute myocardial infarction on admission.~* Electrocardiographic evidence and/or physical findings compatible with second- or third-degree heart block, or of cardiac arrhythmia associated with hemodynamic instability.~* Echocardiogram performed before treatment revealing a left ventricular ejection fraction ≤ 40% (if available).~* Serum creatinine \> 2.0 mg/dl or creatinine clearance \< 50 ml/min.~* Pregnancy, lactation or parturition within previous 30 days.~* Allergy to albumin.~* Severe prior physical disability that precludes evaluation of clinical outcome measures.~* History of chronic lung disease~* Current participation in another drug treatment protocol.~* Severe terminal disease with life expectancy less than 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- dosage tier 1 (Type: ACTIVE_COMPARATOR): 0.625 g/kg 25% human albumin
- dosage tier 2 (Type: ACTIVE_COMPARATOR): 1.25 g/kg 25% human albumin
- dosage tier 3 (Type: ACTIVE_COMPARATOR): 1.875 g/kg 25% human albumin
- dosage tier 4 (Type: ACTIVE_COMPARATOR): 2.5 g/kg 25% human albumin

Based on this trial design, predict the completion outcome and termination type (if applicable).